Ipamorelin vs Somatropin
Ipamorelin is a synthetic pentapeptide that prompts the pituitary to release its own growth hormone by acting at growth hormone secretagogue receptor 1a, the ghrelin receptor. Somatropin is recombinant 191-amino-acid human growth hormone, approved since the mid-1980s, which supplies the hormone directly and carries one of the larger clinical evidence bases in endocrinology. The pairing poses the secretagogue-versus-replacement question, and unusually for this category some direct evidence exists. A 2001 experiment gave growth hormone and ipamorelin to growth hormone-deficient and growth hormone-intact mice in parallel arms and compared what happened to body weight, body fat, leptin and food intake, and a 2006 study administered each in vivo to seabream while mapping ghrelin gene regulation. Both are animal work. No human study has compared a secretagogue against recombinant growth hormone, and the two clinical literatures differ by orders of magnitude in size and in the kind of endpoint they report.
They have been compared directly.
The direct evidence is two animal experiments, neither of them clinical. Lall and colleagues compared twice-daily subcutaneous treatment with growth hormone and with ipamorelin in growth hormone-deficient lit/lit mice and in growth hormone-intact littermates. Ipamorelin produced a small increase in body weight by two weeks that was not further augmented by nine weeks, while growth hormone markedly enhanced body weight in both groups. The effects on fat diverged: ipamorelin increased fat pad weights relative to body weight in both genotypes and raised relative body fat on dual energy X-ray absorptiometry in growth hormone-intact mice, whereas growth hormone decreased relative fat mass in lit/lit mice and had no effect in intact mice. Secretagogue treatment, but not growth hormone, increased serum leptin and food intake, and the authors concluded that secretagogues increase body fat through growth hormone-independent mechanisms that may include increased feeding. A separate 2006 study reported that in vivo administration of growth hormone or of ipamorelin enhanced ghrelin expression in seabream stomach. Everything else that engages both is review or analytical literature.
The 10 studies that tested both
- 01Animal in vivo2001
Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues
Lall S, et al. · Biochemical and Biophysical Research Communications · growth hormone-deficient (lit/lit) mice and growth hormone-intact littermates; parallel twice-daily subcutaneous treatment with growth hormone or with ipamorelin, body composition by dual energy X-ray absorptiometry at two weeks and fat pad weights to nine weeks
Ipamorelin produced a small increase in body weight by two weeks that was not further augmented by nine weeks, whereas growth hormone markedly enhanced body weight in both genotypes. Ipamorelin increased fat pad weights relative to body weight in both lit/lit and heterozygous mice and raised relative body fat on dual energy X-ray absorptiometry in growth hormone-intact mice, while growth hormone decreased relative fat mass in lit/lit mice and had no effect in intact mice. Secretagogue treatment, but not growth hormone, increased serum leptin and food intake, and the authors attributed the adiposity effect to growth hormone-independent mechanisms.
- 02Animal in vivo2006
Seabream ghrelin: cDNA cloning, genomic organization and promoter studies
Yeung CM, et al. · Journal of Endocrinology · black seabream (Acanthopagrus schlegeli); ghrelin cDNA cloning, gene structure and promoter study with in vivo administration of growth hormone or of ipamorelin
Ghrelin expression was detected only in seabream stomach among the tissues examined. In vivo administration of growth hormone or of ipamorelin enhanced that expression, which the authors interpreted as homologous regulation of the ghrelin gene comparable to the regulation previously reported for the seabream growth hormone secretagogue receptor. No metabolic or body-composition endpoint was recorded.
- 03In vitro2018
Analysis of new growth promoting black market products
Krug O, et al. · Growth Hormone & IGF Research · seized black-market growth-promoting preparations; top-down and bottom-up high-resolution mass spectrometry, with custom synthesis for confirmation
Analysis of confiscated products identified a modified growth hormone of 192 amino acids carrying an additional N-terminal alanine, alongside three glycine-extended growth hormone releasing peptides including Gly-ipamorelin, whose identity was confirmed by custom synthesis. The study characterised an altered recombinant growth hormone and a secretagogue analogue circulating in the same illicit market, without administering either.
- 04In vitro2011
Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry
Thomas A, et al. · Analytical and Bioanalytical Chemistry · human urine; extraction and LC-MS detection method for eight growth hormone releasing peptides including ipamorelin
An extraction and mass spectrometric procedure was validated for eight growth hormone releasing peptides including ipamorelin, with limits of detection between 0.2 and 1 ng/mL. The authors set out the rationale that these peptides raise endogenous growth hormone production while the established test for exogenous growth hormone fails to detect their use, leaving the practice unrecognised.
- 05Review2020
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha DK, et al. · Translational Andrology and Urology · narrative review of growth hormone secretagogues as adjuncts in body composition management; ipamorelin among the agents reviewed, growth hormone therapy as the comparator concept
The review examined sermorelin, GHRP-2, GHRP-6, ibutamoren and ipamorelin as potential adjuncts in hypogonadal and eugonadal men, reporting studies in which secretagogue treatment raised growth hormone and IGF-1 towards the levels seen with recombinant growth hormone therapy while preserving pulsatile secretion, in contrast to the persistent supra-therapeutic concentrations attributed to exogenous growth hormone. The authors stated that clinical efficacy data for these compounds were largely lacking.
- 06Review2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, et al. · Frontiers in Endocrinology · narrative review of peptides acting on the GH-IGF-1 axis, set against the history of exogenous growth hormone misuse; ipamorelin among the compounds covered
The review traced performance-oriented use of exogenous growth hormone from the early 1980s onward and then surveyed the peptides now marketed as alternatives, including growth hormone secretagogues such as ipamorelin, proposing a clinical assessment algorithm for patients who self-administer them. The authors reported that clinically meaningful benefit in healthy individuals remained uncertain because the human evidence base was limited and largely indirect.
- 07Review2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, et al. · JBJS Reviews · structured narrative review of injectable peptides published between 2020 and 2025; ipamorelin among the growth hormone axis agents covered
The review classified injectable peptides into five functional classes and found that only glucagon-like peptide-1 agonists carried reproducible randomised evidence for a musculoskeletal indication. Growth hormone axis secretagogues were categorised as experimental, and the authors recommended confining clinical use to approved agents and formal research protocols.
- 08Review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · The American Journal of Sports Medicine · scoping review of six commonly marketed peptides including ipamorelin
The review reported that roughly two-thirds of the retrieved literature comprised preclinical animal work with variable results, and concluded that claimed musculoskeletal recovery benefits of the marketed peptides remained unsubstantiated in humans. Documented cardiovascular and metabolic risks were noted alongside that conclusion.
- 09Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O · Frontiers in Aging · review of nine peptides proposed for healthy ageing; ipamorelin among the growth hormone modulators, exogenous growth hormone as the contrasting approach
The review discussed growth hormone modulators, ipamorelin among them, in the context of the age-related decline in the somatotropic axis, and contrasted secretagogue strategies said to preserve pulsatile release with exogenous growth hormone administration, which it described as suppressing endogenous production and eliminating pulsatility. The authors reported that peptides in this group lacked long-term data and required rigorous clinical validation.
- 10Review2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, et al. · The Journal of Sports Medicine and Physical Fitness · critical review of peptide and peptide-analogue use in recreational and professional sport; ipamorelin named among growth hormone secretagogues
The review traced enhancement practice from anabolic-androgenic steroids to peptides, naming ipamorelin among growth hormone secretagogues promoted as more selective alternatives. It reported that most published studies examined therapeutic applications under controlled conditions rather than the combined regimens used in bodybuilding, flagged cardiovascular, metabolic and psychiatric risks, and noted that structural similarity to endogenous hormones complicates detection.
Side by side.
| Ipamorelin | Somatropin | |
|---|---|---|
| Evidence maturity | Early clinical | Approved drug |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 9 | 13 |
| Newest paper | 2026 | 2026 |
| Molecular class and origin | A synthetic pentapeptide with no endogenous counterpart, characterised in 1998 as the first secretagogue in its class to release growth hormone without elevating ACTH or cortisol significantly above the levels seen after GHRH stimulation. | Recombinant 191-amino-acid human growth hormone, identical to the pituitary hormone, produced by recombinant expression after cadaveric pituitary-derived preparations were abandoned. |
| Where the effect is produced | Upstream, at growth hormone secretagogue receptor 1a in the pituitary and hypothalamus. Output depends on somatotroph reserve and remains subject to hypothalamic control. | Downstream, at the growth hormone receptor through the JAK/STAT pathway and largely via hepatic and local IGF-1 induction, bypassing the pituitary entirely. |
| What the direct comparison found | In the mouse experiment ipamorelin produced only a small early body weight increase, raised fat pad weights relative to body weight in both genotypes, and increased serum leptin and food intake. | Growth hormone markedly increased body weight in both genotypes and decreased relative fat mass in the growth hormone-deficient mice, with no effect on relative fat in intact mice and no rise in leptin or food intake. |
| Regulatory status | No marketing authorisation in any jurisdiction for any indication, and listed among prohibited growth hormone secretagogues in sport. | Approved since the mid-1980s across childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature, with international consensus statements governing its use. |
| Size and design of the human evidence | Two published human datasets: a 1999 dose-escalation pharmacokinetic-pharmacodynamic study in healthy volunteers, and a randomised placebo-controlled phase 2 trial in 114 bowel resection patients that did not meet its primary endpoint. | Network meta-analyses spanning thousands of participants, including an 18-trial network of 3,137 patients and a 16-trial synthesis of 2,435 paediatric patients, alongside a prospective registry of 5,040 children covering 19,878 patient-years. |
| Endpoints measured in humans | Pharmacokinetic parameters, an elimination half-life of approximately two hours, episodic growth hormone release, and time to first tolerated meal after bowel resection. No human body-composition endpoint has been reported. | Height velocity, adult height attainment, body composition, BMI standard deviation score, and long-term surveillance of mortality and malignancy incidence. |
| Long-term safety surveillance | None exists. Long-term human safety, effects on body composition, bone or musculoskeletal recovery, and outcomes in non-surgical populations remain unstudied. | Extensive but qualified. A registry recorded adverse drug reactions in 7.0% of participants and a malignancy standardised incidence ratio of 1.1; a consensus statement found no support for an association with tumour recurrence in survivors; a meta-analysis concluded that selection and time bias precluded high-quality evidence that replacement improves mortality. |
| Direction of contemporary research | Narrative reviews of unapproved peptide use, anti-doping detection methods, and scattered animal work including a ferret model of cisplatin-induced weight loss and a cichlid fish reproductive-axis study. | Long-acting weekly analogues, including somapacitan, somatrogon, lonapegsomatropin and pegylated formulations, benchmarked against daily somatropin, with broadly comparable growth outcomes and a first-year BMI rise reported on the weekly schedule. |
And what it does not.
Two animal experiments placed these compounds side by side, and the more informative of them pointed in opposite directions for the two arms. In growth hormone-deficient and growth hormone-intact mice, exogenous growth hormone markedly increased body weight and reduced relative fat mass in the deficient animals, while ipamorelin produced only a small early weight increase and raised relative body fat, serum leptin and food intake, leading the authors to conclude that secretagogues increase adiposity through growth hormone-independent mechanisms that may include increased feeding. That is a nine-week rodent result, and no human study has compared a secretagogue against recombinant growth hormone. Away from it the two records are not of the same order. Somatropin has decades of randomised trials, network meta-analyses, consensus statements and registry surveillance covering clinical endpoints, together with honest limits around contested diagnostic thresholds and observational mortality data. Ipamorelin has one human pharmacokinetic study, one randomised trial that did not separate from placebo, no approval anywhere, and no published human body-composition data at all.
Common questions.
- Has any published experiment given ipamorelin and growth hormone in the same study?
Yes, in animals. A 2001 experiment compared twice-daily subcutaneous growth hormone and ipamorelin in growth hormone-deficient lit/lit mice and in growth hormone-intact littermates, measuring body weight, fat pad weights, body composition by dual energy X-ray absorptiometry, serum leptin and food intake. A 2006 study of ghrelin gene regulation in seabream also administered growth hormone or ipamorelin in vivo. No human study has compared a growth hormone secretagogue with recombinant human growth hormone within one design, so no clinical comparison exists.
- What did the mouse experiment that included both find about body fat?
The two treatments moved fat in opposite directions. Ipamorelin increased fat pad weights relative to body weight in both growth hormone-deficient and heterozygous mice, and raised relative body fat measured by dual energy X-ray absorptiometry in growth hormone-intact animals. Growth hormone decreased relative fat mass in the deficient mice and had no effect in intact mice. Secretagogue treatment, but not growth hormone, increased serum leptin and food intake, and the authors attributed the adiposity effect to growth hormone-independent mechanisms that may include increased feeding.
- Does a secretagogue work when the pituitary itself is the problem?
The distinction is mechanistic and matters here. Ipamorelin acts at growth hormone secretagogue receptor 1a in the pituitary and hypothalamus, so the response depends on somatotroph reserve and remains subject to hypothalamic control. Somatropin supplies the hormone itself at the growth hormone receptor and does not depend on pituitary output, which is why it is the approved treatment in classical growth hormone deficiency. In the mouse experiment that included both, growth hormone markedly increased body weight in the deficient animals while ipamorelin produced only a small early gain.
- Which of the two has clinical outcome data rather than hormone measurements?
Only somatropin. Its evidence base reports height velocity, adult height attainment, body composition, BMI standard deviation score and long-term surveillance of mortality and malignancy, synthesised in network meta-analyses covering thousands of participants and in international consensus statements. The published human record for ipamorelin consists of a 1999 dose-escalation pharmacokinetic-pharmacodynamic study in healthy volunteers and a randomised placebo-controlled phase 2 trial in bowel resection patients that did not separate from placebo on time to first tolerated meal.
- Why do doping-control and black-market analyses keep naming both?
Because both are used to raise growth hormone activity and both are prohibited in sport, so laboratories and customs analyses encounter them together. A 2018 study of confiscated growth-promoting products identified an altered 192-amino-acid growth hormone carrying an extra N-terminal alanine alongside glycine-extended secretagogue analogues including Gly-ipamorelin. Detection-method papers make the same point from the other direction, noting that secretagogues raise endogenous growth hormone while the established test for exogenous growth hormone does not detect their use.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.